The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
AusPAR: Evusheld
Australian Public Assessment Report
Device/Product Name
Evusheld
Active ingredients
Tixagevimab and cilgavimab
AusPAR Date
Published
Sponsor
Submission Number
PM-2021-05375-1-2 and PM-2022-03097-1-2
Submission Type
New biological entity and change in dosage and change to Product Information requiring evaluation of new data
Decision
Approved for provisional registration